FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Charles Faith L.				<u>C</u>	2. Issuer Name and Ticker or Trading Symbol CNS Pharmaceuticals, Inc. [CNSP]										nship of Reporting Person I applicable) Director		(s) to Issuer	
(Last)	(First)	,	liddle)		3. Date of Earliest Transaction (Month/Day/Year) 12/30/2022								Officer (give title below)			Other (specify below)		
C/O CNS PHARMACEUTICALS, INC. 100 WEST LOOP SOUTH, SUITE 900				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv						
(Street) HOUSTON	TX	77	7027											Form filed	d by More	than C	ne Reportin	g Person
(City)	(State)) (Z	ip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date							2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and 5)			5. Amount Securities Beneficially Following F	For Owned or I		lirect (I) . 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	/ Am	mount (A) or (D)		Price		str. 3 and 4)			(111501.4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			9. Number of derivative Securities Beneficially Owned Following Reported Transaction	e s illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expira Date	ition	Title	o N	Amount or lumber of Shares		(Instr. 4)	011(5)		
Option to purchase common stock	\$2.4	12/30/2022		A		3,500		(1)	12/30/2	2022	Common Stock		3,500	(2)	3,500)	D	

Explanation of Responses:

- 1. The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or December 30, 2022, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.
- $2. \ The \ options \ were \ issued \ in \ connection \ with \ the \ reporting \ person's \ Board \ of \ Director \ services \ to \ the \ Company.$

/s/ Christopher Downs, Attorneyin-fact 01/04/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.